ALNY Alnylam Pharmaceuticals, Inc. - Common Stock
Informazioni su Alnylam Pharmaceuticals, Inc. - Common Stock Panoramica della società da Wikipedia
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Leggi di più
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
History
The company is a spin-off from the Max Planck Institute for Biophysical Chemistry. In 2002, Alnylam was founded by scientists Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore, and by investors Christoph Westphal and John Kennedy Clarke; John Maraganore was the founding CEO. The company was named after Alnilam, a star in Orion's belt. The spelling was modified to make it unique. In 2003, the firm merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms. On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange.
In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders, and in 2006 with Biogen Idec to develop treatments of progressive multifocal leukoencephalopathy. In 2007, it entered into a nonexclusive alliance with Hoffmann-La Roche, in which Alnylam received $331 million in exchange for access to its technology platform. and also partnered with Ionis Pharmaceuticals to found the company Regulus Therapeutics, focused on microRNA therapeutics.
In 2009, the company formed alliances with Cubist Pharmaceuticals and Kyowa Hakko Kirin to market a drug targeted at respiratory syncytial virus. In 2010, it expanded its previous collaboration with Medtronic to include the CHDI Foundation in its Huntington's disease focused research. In 2011, it partnered with GlaxoSmithKline to develop RNAi technology enhancing vaccine production. The company entered into a 10-year alliance with Monsanto in 2012, to develop biotech solutions for the farming industry by developing natural molecules for crop protection. In 2012, it formed a partnership with Sanofi Genzyme to develop a treatment for transthyretin-mediated amyloidosis, a hereditary disease in Asia. In February 2013, it formed a partnership with The Medicines Company to develop a drug to treat a genetic form of high cholesterol.
In July 2013, during a Phase I trial Alnylam demonstrated statistically significant reduction of a protein called transthyretin, or TTR and demonstrated human efficacy with intravenous and subcutaneous modes of administration. In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock. In 2015, the company had $41 million in revenue and a market cap of $5.2 billion.
In 2016, the company purchased land in Norton, Massachusetts to build a manufacturing facility.
In October 2016 the Phase III clinical trial of the company's lead product, revusiran, was halted due to increased deaths in the drug arm of the trial, and the company said it was terminating development of the compound.
On October 10, 2018, Alnylam appoints Margaret Hamburg to Board of Directors. Prior to this, from May 2009 to April 2015, she serves as Commissioner of the U.S. Food and Drug Administration (FDA).
In February 2020, Alnylam appointed former Sanofi CEO Olivier Brandicourt to its board of directors. In 2021, it was announced that Maraganore would step down as CEO, to be succeeded by the company's chief operating officer, Yvonne Greenstreet, on January 1, 2022.
In December 2021, Alnylam submitted a clinical trial authorisation (CTA) application to the Medicines and Healthcare Products Regulatory Agency in the United Kingdom to initiate a Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) for the treatment of Alzheimer's disease and cerebral amyloid angiopathy.
On December 22, 2021, Novartis announced that the US Food and Drug Administration (FDA) approved Leqvio (inclisiran), a small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. Leqvio is indicated in the United States as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality is being explored in clinical trials currently underway. Novartis obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.
Alnylam still does not earn money, but writes losses. The losses ("GAAP Operating Loss") from Alnylam were around $650 million in the late 2020. Alnylam expects to achieve net profits financially in 2022 or 2023.
In July 2023, Roche partnered with Alnylam Pharmaceuticals in a deal worth $2.8 billion for the development of a hypertension drug.
Products
In 2016, Alnylam Pharmaceuticals had 18 potential treatments in various development stages in genetic medicine, cardiometabolic disease and hepatic infectious disease.
Patisiran
In late 2016, the company's lead candidate in phase III studies was patisiran, a treatment targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR), in patients with the compromised nervous system condition of familial amyloidotic polyneuropathy (FAP).
In August 2018, with its commercial name Onpattro, patisiran received the U.S. regulatory approval to treat polyneuropathy in patients with hereditary ATTR amyloidosis.
FDA on patisiran for cardiomyopathy
In September 2023, the FDA raised doubts about the efficacy of patisiran for treating cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR-CM). The FDA's Cardiovascular and Renal Drugs Advisory Committee meeting is scheduled for September 13, 2023. Although the APOLLO-B study met key endpoints, the FDA questioned the clinical significance of the results particularly for patients not on background therapy with tafamidis. The FDA is seeking the committee's input on the clinical meaningfulness and patient populations for patisiran use potentially challenging Pfizer's tafamidis dominance in ATTR-CM treatment. A decision on Alnylam's application is expected by October 8, 2023. Patisiran was previously approved in 2018 for hereditary ATTR amyloidosis polyneuropathy, becoming the first RNA interference therapeutic approved by the FDA. The committee meeting chose to deny approval for the treatment of cardiomyopathy of ATTR amyloidosis with patisiran. Note that while patisiran was denied for the indication of cardiomyopathy, it remains an FDA approved treatment for polyneuropathy.
Vutrisiran
Alnylam went on to pursue the development of vutrisiran, which received FDA approval in 2022 and accounted for the majority of reported profit compared to patisiran/Onpattro in 2025.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
ALNY Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
ALNY Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
ALNY Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
- Acquisto forte 8 21,6%
- Compra 21 56,8%
- Mantieni 8 21,6%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
24 analisti · 2026-08-14Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $1.21 | $1.59 | -0.38% |
| 31 Marzo 2026 | $1.51 | $0.98 | 0.53% |
| 31 Dicembre 2025 | $0.82 | $1.15 | -0.33% |
| 30 Settembre 2025 | $2.11 | $0.76 | 1.3% |
| 30 Giugno 2025 | $-0.51 | $-0.73 | 0.22% |
| 31 Marzo 2025 | $-0.44 | $-1.03 | 0.59% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| RVMD | — | — | — | — | — | — |
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 17
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | · | · | |
| Cost of Revenue | $677M | $307M | $268M | $140M | $115M | $74M | $25M | $2M | $0 | · | · | · | |
| R&D Expense | $1.32B | $1.13B | $1.00B | $883M | $792M | $655M | $655M | $505M | $391M | $382M | $276M | $190M | |
| SG&A Expense | $1.21B | $976M | $796M | $771M | $621M | $588M | $479M | $382M | $199M | $89M | $61M | $45M | |
| Operating Expenses | $3.21B | $2.43B | $2.11B | $1.82B | $1.55B | $1.32B | $1.16B | $890M | $590M | $472M | $337M | $456M | |
| Operating Income | $502M | $-177M | $-282M | $-785M | $-709M | $-828M | $-939M | $-815M | $-500M | $-425M | $-296M | $-405M | |
| Interest Expense | · | · | $121M | $156M | $143M | $84M | $0 | $0 | · | · | · | · | |
| Interest Income | $111M | $122M | $96M | $25M | $2M | $12M | $33M | $29M | · | · | · | · | |
| Other Non-op | $5M | $-181M | $-126M | $-134M | $-2M | $57M | $21M | $25M | $-3M | $6M | $76.0K | $2M | |
| Pretax Income | $323M | $-377M | $-434M | $-1.13B | $-852M | $-856M | $-885M | $-761M | $-491M | $-410M | $-290M | $-401M | |
| Income Tax | $9M | $-99M | $7M | $4M | $680.0K | $3M | $863.0K | $823.0K | $0 | $0 | $0 | $-40M | |
| Net Income | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | · | · | · | · | · | |
| Shares (Basic) | 131,004,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| Shares (Diluted) | 134,684,000 | 127,651,000 | 124,906,000 | 121,689,000 | 118,451,000 | 114,986,000 | 109,264,000 | · | · | · | · | · | |
| EBITDA | $557M | $-120M | $-228M | $-741M | $-661M | $-794M | $-922M | $-808M | $-487M | $-409M | $-277M | $-393M |
Stato Patrimoniale 23
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.66B | $966M | $813M | $866M | $820M | $497M | $547M | $420M | $645M | $194M | $181M | $75M | |
| Receivables | $778M | $405M | $328M | $238M | $199M | $102M | $43M | $19M | $34M | $23M | $8M | $40M | |
| Inventory | $83M | $79M | $89M | $129M | $86M | $75M | $56M | $24M | · | · | · | · | |
| Prepaid Expense | $282M | $117M | $126M | $133M | $88M | $63M | $80M | $74M | $40M | $22M | $17M | $10M | |
| Current Assets | $4.05B | $3.30B | $2.98B | $2.69B | $2.81B | $2.61B | $1.72B | $1.20B | $1.76B | $672M | $1.11B | $746M | |
| PP&E (Net) | $513M | $503M | $526M | $523M | $502M | $465M | $425M | $321M | $182M | $115M | $28M | $22M | |
| PP&E (Gross) | $836M | $773M | $749M | $697M | $642M | $569M | $501M | $400M | $249M | $176M | $79M | $68M | |
| Accum. Depreciation | $323M | $270M | $223M | $173M | $140M | $104M | $76M | $79M | $67M | $61M | $51M | $46M | |
| Other Non-current Assets | $59M | $65M | $62M | $66M | $60M | $45M | $18M | $9M | $4M | $2M | $1M | · | |
| Total Assets | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Accounts Payable | $116M | $88M | $56M | $98M | $73M | $52M | $50M | $60M | $28M | $54M | $17M | $15M | |
| Accrued Liabilities | $1.08B | $794M | $713M | $545M | $395M | $356M | $197M | $113M | $72M | $42M | $29M | $24M | |
| Current Liabilities | $1.47B | $1.19B | $968M | $768M | $696M | $585M | $353M | $179M | $144M | $132M | $62M | $95M | |
| Capital Leases | $225M | $230M | $243M | $261M | $281M | $293M | $276M | · | · | · | · | · | |
| Other Non-current Liabilities | $8M | $5M | $308M | $213M | $99M | $38M | $9M | $5M | $4M | $3M | $1M | · | |
| Total Liabilities | $4.18B | $4.17B | $4.05B | $3.70B | $3.06B | $2.39B | $956M | $273M | $228M | $343M | $122M | $143M | |
| Long-term Debt | · | · | · | · | $676M | $191M | · | · | · | · | · | · | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $997.0K | $859.0K | $851.0K | $772.0K | |
| Retained Earnings | $-6.70B | $-7.29B | $-7.01B | $-6.57B | $-5.44B | $-4.59B | $-3.73B | $-2.84B | $-2.15B | $-1.66B | $-1.25B | $-957M | |
| AOCI | $-20M | $-35M | $-23M | $-45M | $-33M | $-44M | $-37M | $-33M | $-34M | $-33M | $4M | $49M | |
| Stockholders' Equity | $789M | $67M | $-221M | $-158M | $588M | $1.02B | $1.44B | $1.30B | $1.77B | $920M | $1.26B | $936M | |
| Liabilities + Equity | $4.97B | $4.24B | $3.83B | $3.55B | $3.64B | $3.41B | $2.40B | $1.57B | $1.99B | $1.26B | $1.39B | $1.08B | |
| Shares Outstanding | 132,376,000 | 129,294,000 | 125,794,000 | 123,925,000 | 120,182,000 | 116,427,000 | 112,188,000 | 101,177,000 | 99,667,000 | 85,941,000 | 85,090,968 | 77,202,753 |
Flusso di cassa 14
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $56M | $57M | $54M | $44M | $48M | $35M | $17M | $15M | $12M | $15M | $19M | $12M | |
| Stock-based Comp | $348M | $272M | $222M | $231M | $166M | $140M | $175M | $158M | $93M | $76M | $46M | $33M | |
| Deferred Tax | $-2M | $-107M | $-713.0K | $-1M | $-3M | $-3M | $-2M | $-788.0K | $0 | · | · | · | |
| Other Non-cash | $-191M | $48M | $269M | $316M | $614.0K | $72M | $418M | $35M | $2M | $12M | $36M | $150M | |
| Operating Cash Flow | $524M | $-8M | $104M | $-541M | $-642M | $-615M | $-278M | $-563M | $-383M | $-308M | $-189M | $-166M | |
| CapEx | $59M | $34M | $62M | $72M | $76M | $70M | $140M | $127M | $104M | $65M | $13M | $9M | |
| Investing Cash Flow | $436M | $-117M | $-336M | $169M | $-273M | $-436M | $-418M | $273M | $-290M | $143M | · | · | |
| Stock Issued | · | · | · | · | $0 | $0 | $382M | $0 | $1.14B | · | $496M | · | |
| Net Stock Activity | · | · | · | · | $0 | $0 | $382M | · | $1.14B | · | $496M | · | |
| Financing Cash Flow | $-305M | $294M | $172M | $426M | $1.25B | $995M | $823M | $65M | $1.12B | $178M | · | · | |
| Net Change in Cash | $690M | $154M | $-54M | $46M | $323M | $-51M | $127M | $-224M | $452M | $13M | $106M | $22M | |
| Taxes Paid | $15M | $14M | $6M | $3M | · | · | · | · | · | $111.0K | $66.0K | $-517.0K | |
| Free Cash Flow | $465M | $-43M | $42M | $-613M | $-718M | $-685M | $-419M | $-690M | $-487M | $-372M | $-202M | $-175M | |
| Levered FCF | · | · | $-81M | $-770M | $-861M | $-770M | · | · | · | · | · | · |
Redditività 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1087.6% | · | · | · | · | |
| Net Margin | 8.5% | -12.4% | -24.1% | -109.0% | -101.0% | -174.2% | -403.2% | -1016.6% | · | · | · | · | |
| Pretax Margin | 8.7% | -16.8% | -23.7% | -108.6% | -100.9% | -173.6% | -402.9% | -1015.5% | · | · | · | · | |
| EBITDA Margin | 15.0% | -5.3% | -12.5% | -71.4% | -78.3% | -161.0% | -419.7% | -1079.0% | · | · | · | · | |
| ROA | 6.8% | -6.9% | -11.9% | -31.5% | -24.2% | -29.6% | -44.6% | -42.7% | -30.1% | -31.0% | -23.5% | -48.0% | |
| ROE | 60.4% | -559.4% | 227.8% | 1001.6% | -126.9% | -76.9% | -58.2% | -54.8% | -36.5% | -37.5% | -26.4% | -59.7% | |
| ROIC | 61.7% | -194.3% | 129.9% | 498.0% | -120.6% | -81.8% | -65.4% | -62.6% | · | · | -23.4% | -38.9% |
Liquidità e Solvibilità 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 | 4.5 | 4.9 | 6.7 | 12.2 | 5.1 | 17.8 | 7.8 | |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 | 1.0 | 1.7 | 2.4 | 4.7 | 1.6 | 3.0 | 1.2 | |
| Interest Coverage | · | · | -2.3 | -5.0 | -5.0 | -9.8 | · | · | · | · | · | · |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.8 | 0.6 | 0.5 | 0.3 | 0.2 | 0.2 | 0.1 | 0.0 | · | · | · | · | |
| Inventory Turnover | 8.4 | 3.7 | 2.5 | 1.3 | 1.4 | 1.2 | 0.6 | 0.1 | · | · | · | · | |
| Receivables Turnover | 6.3 | 6.1 | 6.5 | 4.8 | 5.6 | 6.8 | 7.1 | 2.8 | · | · | · | · |
Tassi di Crescita 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 65.2% | 23.0% | 76.2% | 22.9% | 71.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 53.0% | 38.6% | 54.8% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 49.8% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 10
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.71B | $2.25B | $1.83B | $1.04B | $844M | $493M | $220M | $75M | $90M | $47M | $100M | $100M | |
| Net Income TTM | $314M | $-278M | $-440M | $-1.13B | $-853M | $-858M | $-886M | $-761M | $-491M | $-410M | $-290M | $-360M | |
| Market Cap | $52.64B | $30.42B | $24.08B | $29.45B | $20.38B | $15.13B | $12.92B | $7.38B | $12.66B | $3.22B | $8.01B | $7.49B | |
| P/E | 170.7 | -107.9 | -54.4 | -25.6 | -23.6 | -17.4 | -14.2 | · | · | · | · | · | |
| P/S | 14.2 | 13.5 | 13.2 | 28.4 | 24.1 | 30.7 | 58.8 | 98.5 | 140.8 | 68.2 | 80.3 | 75.1 | |
| P/B | 66.7 | 453.5 | -109.1 | -186.1 | 34.6 | 14.9 | 9.0 | 5.7 | 7.2 | 3.5 | 6.3 | 8.0 | |
| P / Tangible Book | 66.7 | 453.5 | · | · | 34.6 | 14.9 | · | · | · | · | · | · | |
| P / Cash Flow | 100.4 | -3660.3 | 231.2 | -54.4 | -31.8 | -24.6 | -46.4 | -13.1 | -33.1 | -10.5 | -42.4 | -45.2 | |
| P / FCF | 113.1 | -714.4 | 574.0 | -48.0 | -28.4 | -22.1 | -30.9 | -10.7 | -26.0 | -8.6 | -39.6 | -42.9 | |
| Earnings Yield | 0.59% | -0.93% | -1.8% | -3.9% | -4.2% | -5.7% | -7.0% | · | · | · | · | · |
Conto Economico 17
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.29B | $1.17B | $1.10B | $1.25B | $774M | $594M | $593M | $501M | $660M | $494M | $440M | $751M | $319M | $319M | $335M | $264M | |
| Cost of Revenue | $298M | $208M | $268M | $197M | $142M | $70M | $103M | $82M | $67M | $55M | $72M | $79M | $75M | $41M | $46M | $37M | |
| R&D Expense | $413M | $365M | $372M | $359M | $324M | $265M | $300M | $271M | $294M | $261M | $272M | $253M | $249M | $231M | $262M | $245M | |
| SG&A Expense | $348M | $323M | $325M | $322M | $323M | $240M | $295M | $221M | $248M | $211M | $198M | $199M | $215M | $184M | $210M | $236M | |
| Operating Expenses | $1.06B | $899M | $965M | $881M | $790M | $576M | $698M | $578M | $611M | $538M | $556M | $537M | $549M | $469M | $524M | $522M | |
| Operating Income | $231M | $269M | $132M | $368M | $-16M | $18M | $-105M | $-77M | $49M | $-43M | $-116M | $214M | $-230M | $-150M | $-189M | $-258M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $31M | $30M | $29M | · | $41M | |
| Interest Income | $28M | $27M | $27M | $29M | $27M | $29M | $31M | $32M | $29M | $30M | $30M | $25M | $21M | $19M | $14M | $8M | |
| Other Non-op | $273.0K | $-4M | $135M | $-74M | $9M | $9M | $-81M | $-30M | $-56M | $-15M | $-20M | $-58M | $-35M | $-12M | $-3M | $-38M | |
| Pretax Income | $178M | $222M | $161M | $239M | $-41M | $-2M | $-194M | $-109M | $-11M | $-64M | $-138M | $151M | $-274M | $-172M | $-207M | $-406M | |
| Income Tax | $13M | $16M | $-25M | $-12M | $31M | $16M | $-110M | $3M | $6M | $2M | $183.0K | $3M | $2M | $2M | $472.0K | $-23.0K | |
| Net Income | $164M | $206M | $186M | $251M | $-72M | $-18M | $-84M | $-112M | $-17M | $-66M | $-138M | $148M | $-276M | $-174M | $-207M | $-406M | |
| EPS (Basic) | $1.23 | $1.55 | $1.43 | $1.91 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.09 | $1.18 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| EPS (Diluted) | $1.21 | $1.51 | $1.44 | $1.84 | $-0.55 | $-0.14 | $-0.66 | $-0.87 | $-0.13 | $-0.52 | $-1.06 | $1.15 | $-2.21 | $-1.40 | $-1.69 | $-3.32 | |
| Shares (Basic) | 133,606,000 | 132,893,000 | -260,747,000 | 131,447,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -249,084,000 | 125,220,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| Shares (Diluted) | 138,281,000 | 138,226,000 | -262,968,000 | 137,348,000 | 130,628,000 | 129,676,000 | -253,810,000 | 128,590,000 | 126,733,000 | 126,138,000 | -255,201,000 | 131,337,000 | 124,659,000 | 124,111,000 | -241,766,000 | 122,166,000 | |
| EBITDA | $231M | $282M | · | $368M | $-16M | $32M | · | $-77M | $49M | $-30M | · | $214M | $-230M | $-136M | · | $-258M |
Stato Patrimoniale 22
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.71B | $1.71B | $1.66B | $1.49B | $1.11B | $1.02B | $966M | $1.10B | $968M | $682M | $813M | $1.03B | $658M | $672M | $866M | $1.07B | |
| Receivables | $913M | $884M | $778M | $965M | $567M | $418M | $405M | $354M | $309M | $321M | · | $325M | $221M | $219M | · | $185M | |
| Inventory | $97M | $84M | $83M | $75M | $72M | $66M | $79M | $76M | $84M | $94M | · | $96M | $100M | $132M | · | $115M | |
| Prepaid Expense | $302M | $242M | $282M | $188M | $147M | $152M | $117M | $145M | $155M | $202M | · | $158M | $145M | $119M | · | $126M | |
| Current Assets | $4.62B | $4.22B | $4.05B | $3.95B | $3.64B | $3.27B | $3.30B | $3.36B | $3.17B | $2.99B | · | $2.99B | $2.52B | $2.54B | · | $2.69B | |
| PP&E (Net) | $554M | $518M | $513M | $502M | $500M | $499M | $503M | $507M | $517M | $523M | · | $526M | $527M | $523M | · | $515M | |
| PP&E (Gross) | · | · | $836M | · | · | · | $773M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $323M | · | · | · | $270M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $65M | $64M | $59M | $56M | $57M | $74M | $65M | $78M | $72M | $67M | · | $75M | $93M | $63M | · | $61M | |
| Total Assets | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Accounts Payable | $108M | $127M | $116M | $118M | $102M | $97M | $88M | $71M | $74M | $78M | · | $74M | $60M | $62M | · | $41M | |
| Accrued Liabilities | $1.10B | $946M | $1.08B | $1.15B | $919M | $704M | $794M | $946M | $809M | $699M | · | $713M | $599M | $509M | · | $511M | |
| Current Liabilities | $1.51B | $1.35B | $1.47B | $1.56B | $1.30B | $1.08B | $1.19B | $1.22B | $1.06B | $942M | · | $950M | $789M | $673M | · | $773M | |
| Capital Leases | $210M | $218M | $225M | $223M | $224M | $230M | $230M | $236M | $239M | $238M | · | $248M | $253M | $259M | · | $266M | |
| Other Non-current Liabilities | $9M | $8M | $8M | $10M | $11M | $6M | $5M | $357M | $350M | $320M | · | $281M | $257M | $224M | · | $183M | |
| Total Liabilities | $4.20B | $4.05B | $4.18B | $4.62B | $4.32B | $4.10B | $4.17B | $4.17B | $4.01B | $4.04B | · | $4.00B | $3.81B | $3.65B | · | $3.60B | |
| Common Stock | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | · | $1M | $1M | $1M | · | $1M | |
| Retained Earnings | $-6.33B | $-6.50B | $-6.70B | $-7.16B | $-7.41B | $-7.35B | $-7.29B | $-7.20B | $-7.09B | $-7.08B | · | $-6.87B | $-7.02B | $-6.74B | · | $-6.36B | |
| AOCI | $-32M | $-25M | $-20M | $-22M | $-30M | $-38M | $-35M | $-25M | $-35M | $-27M | · | $-32M | $-37M | $-39M | · | $-44M | |
| Stockholders' Equity | $1.35B | $1.08B | $789M | $234M | $251M | $115M | $67M | $32M | $-3M | $-219M | $-221M | $-166M | $-408M | $-259M | $-158M | $-68M | |
| Liabilities + Equity | $5.56B | $5.13B | $4.97B | $4.85B | $4.57B | $4.21B | $4.24B | $4.21B | $4.01B | $3.82B | · | $3.84B | $3.40B | $3.39B | · | $3.54B | |
| Shares Outstanding | 133,734,000 | 133,444,000 | 132,376,000 | 131,791,000 | 130,977,000 | 130,311,000 | 129,294,000 | 128,841,000 | 128,021,000 | 126,463,000 | 125,794,000 | 125,454,000 | 124,901,000 | 124,241,000 | 123,925,000 | 122,991,000 |
Flusso di cassa 12
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $15M | $14M | $13M | $13M | $13M | $14M | $14M | $11M | |
| Stock-based Comp | $87M | $70M | $72M | $108M | $112M | $57M | $92M | $46M | $89M | $45M | $42M | $64M | $76M | $40M | $43M | $128M | |
| Deferred Tax | $3M | $9M | $-27M | $6M | $10M | $10M | $-107M | $-163.0K | $340.0K | $454.0K | · | · | · | · | · | · | |
| Other Non-cash | · | $-229M | · | · | · | $-142M | · | · | · | $-74M | · | · | · | $-46M | · | · | |
| Operating Cash Flow | $327M | $71M | $164M | $325M | $154M | $-120M | $-95M | $44M | $124M | $-82M | $-30M | $359M | $-59M | $-166M | $-132M | $-115M | |
| CapEx | $35M | $22M | $23M | $12M | $14M | $9M | $9M | $4M | $8M | $13M | $15M | $17M | $16M | $14M | $22M | $17M | |
| Investing Cash Flow | $-363M | $-26M | $-37M | $501M | $-141M | $114M | $-53M | $-30M | $34M | $-68M | $-241M | $-11M | $-9M | $-76M | $-140M | $314M | |
| Financing Cash Flow | $36M | $16M | $45M | $-448M | $54M | $46M | $31M | $103M | $131M | $29M | $39M | $33M | $53M | $46M | $63M | $297M | |
| Net Change in Cash | $-3M | $54M | $166M | $377M | $94M | $54M | $-134M | $131M | $286M | $-130M | $-220M | $375M | $-14M | $-194M | $-207M | $498M | |
| Taxes Paid | $12M | $2M | $13M | $1M | $-2M | $3M | · | $5M | $2M | $2M | · | · | · | · | · | · | |
| Free Cash Flow | · | $49M | · | · | · | $-127M | · | · | · | $-94M | · | · | · | $-180M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-131M | · | · | · | $-210M | · | · |
Redditività 7
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 17.9% | 23.0% | · | 29.5% | -2.1% | 3.0% | · | -15.3% | 7.4% | -8.8% | · | 28.5% | -72.1% | -46.9% | · | -97.6% | |
| Net Margin | 12.7% | 17.6% | · | 20.1% | -8.6% | -9.7% | · | -22.3% | -2.6% | -13.3% | · | 19.7% | -86.6% | -54.5% | · | -153.6% | |
| Pretax Margin | 13.8% | 19.0% | · | 19.1% | -4.6% | -7.0% | · | -21.7% | -1.7% | -12.9% | · | 20.1% | -86.0% | -54.0% | · | -153.6% | |
| EBITDA Margin | 17.9% | 24.2% | · | 29.5% | -2.1% | 5.5% | · | -15.3% | 7.4% | -6.0% | · | 28.5% | -72.1% | -42.5% | · | -97.6% | |
| ROA | 3.2% | 4.4% | · | 5.5% | -1.6% | -1.4% | · | -2.8% | -0.46% | -1.8% | · | 4.0% | -8.2% | -5.1% | · | -11.6% | |
| ROE | 20.5% | 34.6% | · | 188.6% | -53.5% | 110.7% | · | 167.1% | 8.2% | 27.6% | · | -126.6% | 237.9% | -245.3% | · | -118.0% | |
| ROIC | 15.8% | 23.2% | · | 165.3% | -12.1% | 21.6% | · | -244.1% | -2397.3% | 20.5% | · | -126.4% | 56.7% | 58.4% | · | 381.5% |
Liquidità e Solvibilità 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | 3.1 | · | 2.5 | 2.8 | 3.0 | · | 2.7 | 3.0 | 3.2 | · | 3.1 | 3.2 | 3.8 | · | 3.5 | |
| Quick Ratio | 1.7 | 1.9 | · | 1.6 | 1.3 | 1.3 | · | 1.2 | 1.2 | 1.1 | · | 1.4 | 1.1 | 1.3 | · | 1.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -1.2 | · | 6.9 | -7.7 | -5.2 | · | -6.3 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.2 | · | 0.3 | 0.2 | 0.1 | · | 0.1 | 0.2 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 3.5 | 2.8 | · | 2.6 | 1.8 | 0.9 | · | 1.0 | 0.7 | 0.5 | · | 0.8 | 0.8 | 0.4 | · | 0.3 | |
| Receivables Turnover | 1.7 | 1.8 | · | 1.9 | 1.8 | 1.6 | · | 1.5 | 2.5 | 1.8 | · | 2.9 | 1.8 | 1.7 | · | 1.6 |
Valutazione (TTM) 10
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.48B | $3.78B | · | $3.12B | $2.53B | $2.25B | · | $2.41B | $2.22B | $1.88B | · | $1.65B | $1.13B | $1.02B | · | $890M | |
| Net Income TTM | $549M | $373M | · | $55M | $-213M | $-213M | · | $-47M | $-211M | $-368M | · | $-708M | $-1.13B | $-1.10B | · | $-1.13B | |
| Market Cap | $40.26B | $44.15B | · | $60.10B | $42.71B | $35.19B | · | $35.44B | $31.11B | $18.90B | · | $22.22B | $23.72B | $24.89B | · | $24.62B | |
| P/E | 75.1 | 122.5 | · | 1425.0 | -197.6 | -162.7 | · | -743.3 | -142.1 | -50.2 | · | -30.6 | -20.6 | -22.2 | · | -21.5 | |
| P/S | 9.0 | 11.7 | · | 19.3 | 16.9 | 15.6 | · | 14.7 | 14.0 | 10.0 | · | 13.4 | 21.0 | 24.4 | · | 27.7 | |
| P/B | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | -10143.2 | -86.2 | · | -134.0 | -58.1 | -96.0 | · | -364.0 | |
| P / Tangible Book | 29.7 | 41.1 | · | 256.9 | 170.4 | 304.8 | · | 1095.2 | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | 626.2 | · | · | · | -297.4 | · | · | · | -231.9 | · | · | · | -149.5 | · | · | |
| P / FCF | · | 907.2 | · | · | · | -276.4 | · | · | · | -200.0 | · | · | · | -138.0 | · | · | |
| Earnings Yield | 1.3% | 0.82% | · | 0.07% | -0.51% | -0.61% | · | -0.13% | -0.70% | -2.0% | · | -3.3% | -4.9% | -4.5% | · | -4.7% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $3.71B | $2.25B | $1.83B | $1.04B | $844M |
| Margine Operativo % | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% |
| Utile netto | $314M | $-278M | $-440M | $-1.13B | $-853M |
| EPS Diluito | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Rapporto corrente | 2.8 | 2.8 | 3.1 | 3.5 | 4.0 |
| Quick Ratio | 1.7 | 1.2 | 1.2 | 1.4 | 1.5 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $465M | $-43M | $42M | $-613M | $-718M |
Ultime notizie Notizie recenti che menzionano questa società
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 877 filer · $27.1B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 99 (-11 vs trimestre precedente) | 77 (-68 vs trimestre precedente) | 328 (+4 vs trimestre precedente) | 259 (+4 vs trimestre precedente) | +15.9M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| Capital World Investors | $3.354.715.611 | 11.144.846 | 12,36% | Azioni |
| FMR LLC | $3.108.157.652 | 10.325.076 | 11,45% | Azioni |
| Capital Research Global Investors | $2.935.115.324 | 9.750.699 | 10,81% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1.968.251.542 | 6.538.390 | 7,25% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.815.053.762 | 6.029.478 | 6,69% | Azioni |
| STATE STREET CORP | $1.070.369.060 | 3.555.689 | 3,94% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $686.853.582 | 2.288.725 | 2,53% | Azioni |
| NORGES BANK | $683.883.867 | 2.271.813 | 2,52% | Azioni |
| WELLINGTON MANAGEMENT GROUP LLP | $614.923.915 | 2.042.733 | 2,26% | Azioni |
| Dodge & Cox | $588.631.955 | 1.955.393 | 2,17% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $564.713.315 | 1.875.937 | 2,08% | Azioni |
| AMERICAN CENTURY COMPANIES INC | $558.098.292 | 1.853.956 | 2,06% | Azioni |
| TWO SIGMA ADVISERS, LP | $450.362.484 | 1.132.560 | 1,66% | Azioni |
| Clearbridge Investments, LLC | $379.142.285 | 1.259.483 | 1,40% | Azioni |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $269.059.154 | 893.795 | 0,99% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $259.723.265 | 862.782 | 0,96% | Azioni |
| Deep Track Capital, LP | $248.349.750 | 825.000 | 0,91% | Azioni |
| Qube Research & Technologies Ltd | $240.437.176 | 798.715 | 0,89% | Azioni |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $219.642.021 | 729.635 | 0,81% | Azioni |
| BANK OF AMERICA CORP /DE/ | $176.408.397 | 586.016 | 0,65% | Azioni |
| LOOMIS SAYLES & CO L P | $170.456.431 | 566.244 | 0,63% | Azioni |
| BAILLIE GIFFORD & CO | $165.849.468 | 550.940 | 0,61% | Azioni |
| ROYAL BANK OF CANADA | $154.998.000 | 514.893 | 0,57% | Azioni |
| Polar Capital Holdings Plc | $145.322.534 | 482.751 | 0,54% | Azioni |
| Paradigm Biocapital Advisors LP | $144.494.400 | 480.000 | 0,53% | Azioni |
| D. E. Shaw & Co., Inc. | $129.533.209 | 430.300 | 0,48% | Opzione Call |
| FIRST TRUST ADVISORS LP | $126.894.361 | 421.534 | 0,47% | Azioni |
| Swiss National Bank | $112.609.302 | 374.080 | 0,41% | Azioni |
| WELLS FARGO & COMPANY/MN | $111.381.100 | 370.000 | 0,41% | Opzione Call |
| BlackRock, Inc. | $102.807.465 | 341.519 | 0,38% | Azioni |
| CANADA PENSION PLAN INVESTMENT BOARD | $100.618.073 | 334.246 | 0,37% | Azioni |
| Sumitomo Mitsui Trust Group, Inc. | $97.948.840 | 325.379 | 0,36% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $97.804.647 | 324.900 | 0,36% | Opzione Call |
| Legal & General Group Plc | $97.467.493 | 323.780 | 0,36% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $95.125.781 | 316.001 | 0,35% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $94.687.695 | 314.546 | 0,35% | Azioni |
| Candriam S.C.A. | $94.586.456 | 314.512 | 0,35% | Azioni |
| D. E. Shaw & Co., Inc. | $93.229.593 | 309.702 | 0,34% | Azioni |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $90.367.000 | 300.193 | 0,33% | Azioni |
| DEUTSCHE BANK AG\ | $89.849.026 | 298.472 | 0,33% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $88.641.294 | 294.460 | 0,33% | Azioni |
| Pictet Asset Management Holding SA | $83.257.214 | 278.613 | 0,31% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $81.586.054 | 271.023 | 0,30% | Azioni |
| GILDER GAGNON HOWE & CO LLC | $80.992.374 | 269.051 | 0,30% | Azioni |
| CONGRESS ASSET MANAGEMENT CO | $79.983.972 | 265.701 | 0,29% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $77.578.441 | 257.710 | 0,29% | Azioni |
| California Public Employees Retirement System | $76.477.575 | 254.053 | 0,28% | Azioni |
| WESTFIELD CAPITAL MANAGEMENT CO LP | $75.974.872 | 252.383 | 0,28% | Azioni |
| Korea Investment CORP | $74.553.090 | 247.660 | 0,27% | Azioni |
| Woodline Partners LP | $74.138.270 | 246.282 | 0,27% | Azioni |
| Squarepoint Ops LLC | $70.440.719 | 233.999 | 0,26% | Azioni |
| TD Asset Management Inc | $70.349.507 | 233.696 | 0,26% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $65.136.061 | 196.863 | 0,24% | Azioni |
| ROYAL LONDON ASSET MANAGEMENT LTD | $64.296.696 | 213.589 | 0,24% | Azioni |
| National Pension Service | $59.692.744 | 198.295 | 0,22% | Azioni |
| PINEBRIDGE INVESTMENTS LLC | $58.914.280 | 195.709 | 0,22% | Azioni |
| Robeco Institutional Asset Management B.V. | $56.618.929 | 188.084 | 0,21% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $53.824.164 | 178.800 | 0,20% | Opzione Put |
| VICTORY CAPITAL MANAGEMENT INC | $52.030.628 | 172.842 | 0,19% | Azioni |
| Mitsubishi UFJ Asset Management Co., Ltd. | $50.772.924 | 168.664 | 0,19% | Azioni |
| RHUMBLINE ADVISERS | $49.844.185 | 165.579 | 0,18% | Azioni |
| Life Cycle Investment Partners Ltd | $49.797.587 | 165.424 | 0,18% | Azioni |
| ANTIPODES PARTNERS Ltd | $49.228.339 | 163.533 | 0,18% | Azioni |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $47.228.883 | 157.223 | 0,17% | Azioni |
| CAPITAL FUND MANAGEMENT S.A. | $46.931.781 | 155.904 | 0,17% | Azioni |
| Assenagon Asset Management S.A. | $46.868.866 | 155.695 | 0,17% | Azioni |
| Vinva Investment Management Ltd | $45.487.381 | 154.972 | 0,17% | Azioni |
| JANUS HENDERSON GROUP PLC | $43.671.202 | 132.000 | 0,16% | Azioni |
| Hudson Bay Capital Management LP | $42.204.406 | 140.200 | 0,16% | Azioni |
| ENVESTNET ASSET MANAGEMENT INC | $41.059.106 | 136.395 | 0,15% | Azioni |
| ProShare Advisors LLC | $38.686.569 | 128.514 | 0,14% | Azioni |
| GOLDMAN SACHS GROUP INC | $37.029.700 | 123.010 | 0,14% | Azioni |
| LMR Partners LLP | $35.881.572 | 119.196 | 0,13% | Azioni |
| Man Group plc | $35.798.187 | 118.919 | 0,13% | Azioni |
| HSBC HOLDINGS PLC | $35.754.282 | 120.600 | 0,13% | Opzione Put |
| SCS Capital Management LLC | $34.783.715 | 115.549 | 0,13% | Azioni |
| AVIVA PLC | $34.477.568 | 114.532 | 0,13% | Azioni |
| Davern Capital Partners, LP | $34.041.978 | 113.085 | 0,13% | Azioni |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $33.770.750 | 112.184 | 0,12% | Azioni |
| Longaeva Partners L.P. | $33.191.869 | 110.261 | 0,12% | Azioni |
| 683 Capital Management, LLC | $32.360.725 | 107.500 | 0,12% | Opzione Put |
| MARSHALL WACE, LLP | $32.215.929 | 107.019 | 0,12% | Azioni |
| HighTower Advisors, LLC | $31.621.666 | 105.045 | 0,12% | Azioni |
| Bridgewater Associates, LP | $29.977.772 | 99.584 | 0,11% | Azioni |
| Prosight Management, LP | $29.525.022 | 98.080 | 0,11% | Azioni |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $28.956.123 | 96.408 | 0,11% | Azioni |
| Andra AP-fonden | $28.685.436 | 86.697 | 0,11% | Azioni |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $28.376.894 | 94.266 | 0,10% | Azioni |
| AMERIPRISE FINANCIAL INC | $28.191.159 | 93.649 | 0,10% | Azioni |
| BARCLAYS PLC | $27.979.234 | 92.945 | 0,10% | Azioni |
| TREMBLANT CAPITAL GROUP | $27.977.728 | 92.940 | 0,10% | Azioni |
| FIL Ltd | $27.652.616 | 91.860 | 0,10% | Azioni |
| Balyasny Asset Management L.P. | $26.945.195 | 89.510 | 0,10% | Azioni |
| Caisse de depot et placement du Quebec | $25.812.720 | 85.748 | 0,10% | Azioni |
| Mitsubishi UFJ Trust & Banking Corp | $24.911.136 | 82.753 | 0,09% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $24.661.883 | 81.925 | 0,09% | Azioni |
| CITADEL ADVISORS LLC | $24.564.048 | 81.600 | 0,09% | Opzione Call |
| VANGUARD GROUP INC | $24.356.460 | 61.251 | 0,09% | Azioni |
| NEOS Investment Management LLC | $23.562.822 | 78.274 | 0,09% | Azioni |
| JONES FINANCIAL COMPANIES LLLP | $23.444.213 | 80.462 | 0,09% | Azioni |
Insider aziendali 41 insider · 1 dirigenti · 13 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Melissa Mclaughlin | Chief Human Resources Officer | 06 Aprile 2026 S | 9.443 | 0 | 14 | $-1.274.343 |
| Colleen F Reitan | Direttore | 20 Maggio 2026 A | 1.446 | 0 | 0 | $0 |
| Charles Elliott Sigal | Direttore | 20 Maggio 2026 A | 1.446 | 0 | 0 | $0 |
| Stuart A Arbuckle | Direttore | 20 Maggio 2026 A | 671 | 0 | 0 | $0 |
| Olivier Brandicourt | Direttore | 20 Maggio 2026 A | 1.446 | 0 | 0 | $0 |
| Amy Schulman | Direttore | 20 Maggio 2026 A | 24.049 | 0 | 0 | $0 |
| Dennis A Ausiello | Direttore | 20 Maggio 2026 A | 1.582 | 0 | 0 | $0 |
| Margaret A Hamburg | Direttore | 20 Maggio 2026 A | 1.582 | 0 | 0 | $0 |
| KELLOGG PETER N | Direttore | 20 Maggio 2026 A | 1.446 | 0 | 0 | $0 |
| David E I Pyott | Direttore | 20 Maggio 2026 A | 1.582 | 0 | 0 | $0 |
| Victor J Dzau | Direttore | 21 Giugno 2012 A | — | 0 | 0 | $0 |
| Peter Barrett | Direttore | 01 Giugno 2006 A | 5.293 | 0 | 0 | $0 |
| John E Berriman | Direttore | 08 Giugno 2005 A | 2.475 | 0 | 0 | $0 |
| Christoph H Westphal | Direttore | 03 Giugno 2004 C | 2.409.970 | 0 | 0 | $0 |
| Sanofi | Proprietario del 10% | 31 Maggio 2017 P | 10.554.134 | 0 | 0 | $0 |
| ALNYLAM PHARMACEUTICALS, INC. | Proprietario del 10% | 23 Febbraio 2016 S | 4.896.716 | 0 | 0 | $0 |
| POLARIS VENTURE MANAGEMENT CO III LLC | Proprietario del 10% | 03 Giugno 2004 C | 2.409.970 | 0 | 0 | $0 |
| CHP II LP | Proprietario del 10% | 27 Maggio 2004 P | 232.500 | 0 | 0 | $0 |
| Akshay Vaishnaw | — | 10 Agosto 2018 A | 395 | 0 | 0 | $0 |
| Barry E Greene | — | 10 Agosto 2018 A | 9.030 | 0 | 0 | $0 |
| John Maraganore | — | 10 Agosto 2018 A | 151.297 | 0 | 0 | $0 |
| SHARP PHILLIP A | — | 09 Marzo 2018 M | 140.795 | 0 | 0 | $0 |
| Michael Mason | — | 04 Gennaio 2018 M | 0 | 0 | 0 | $0 |
| Laurie Keating | — | 29 Dicembre 2017 M | 14.500 | 0 | 0 | $0 |
| Yvonne Greenstreet | — | 20 Dicembre 2017 A | — | 0 | 0 | $0 |
| David-Alexandre C Gros | — | 20 Dicembre 2016 A | — | 0 | 0 | $0 |
| SCHIMMEL PAUL | — | 19 Novembre 2015 G | 306.996 | 0 | 0 | $0 |
| Marsha Fanucci | — | 01 Giugno 2015 A | 10.000 | 0 | 0 | $0 |
| Steven M Paul | — | 01 Giugno 2015 A | — | 0 | 0 | $0 |
| Michael W Bonney | — | 01 Giugno 2015 A | — | 0 | 0 | $0 |
| John K Clarke | — | 01 Giugno 2015 A | 2.091.868 | 0 | 0 | $0 |
| Kevin P Starr | — | 01 Giugno 2015 A | — | 0 | 0 | $0 |
| Laurence Reid | — | 19 Maggio 2014 M | 3.905 | 0 | 0 | $0 |
| Kenneth S Koblan | — | 08 Dicembre 2010 A | — | 0 | 0 | $0 |
| Patricia L Allen | — | 08 Dicembre 2010 A | 0 | 0 | 0 | $0 |
| James L Vincent | — | 18 Giugno 2010 M | 0 | 0 | 0 | $0 |
| Vicki L Sato | — | 02 Giugno 2010 A | — | 0 | 0 | $0 |
| Edward M Scolnick | — | 11 Giugno 2009 A | — | 0 | 0 | $0 |
| John A Schmidt Jr | — | 09 Dicembre 2008 A | — | 0 | 0 | $0 |
| Vincent J Miles | — | 07 Dicembre 2005 A | — | 0 | 0 | $0 |
| Abingworth Management LTD | — | 03 Giugno 2004 C | 18.745 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 2 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| CHP II, L.P. IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum ×2 depositi | 14 Febbraio 2007 | — | Deposito iniziale | — | SEC |
| CHP II, L.P IRSN, CHP II Management LLC IRSN, John K. Clarke, Brandon H. Hull, John J. Park, Lisa M. Skeete Tatum | 15 Febbraio 2006 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 150 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 3,25% | 53.807 SH | 08 Agosto 2026 | Giornaliero |
| NUMG · Nushares ETF Trust | 3,23% | 36.910 NS | 30 Aprile 2026 | N-PORT |
| MID · AMERICAN CENTURY ETF TRUST | 3,19% | 10.523 NS | 31 Maggio 2026 | N-PORT |
| FMED · Fidelity Covington Trust | 2,79% | 3.791 NS | 31 Maggio 2026 | N-PORT |
| IBB · iShares Trust | 2,21% | 976.319 SH | 08 Agosto 2026 | Giornaliero |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 2,01% | 3.468 NS | 30 Aprile 2026 | N-PORT |
| BIB · ProShares Trust | 2,01% | 4.904 NS | 31 Maggio 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,99% | 7.268 SH | 08 Agosto 2026 | Giornaliero |
| FDG · AMERICAN CENTURY ETF TRUST | 1,94% | 26.515 NS | 31 Maggio 2026 | N-PORT |
| JMID · Janus Detroit Street Trust | 1,40% | 824 NS | 30 Aprile 2026 | N-PORT |
| CAML · Professionally Managed Portfolios | 1,29% | 15.623 NS | 30 Aprile 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,24% | 2.379 NS | 30 Aprile 2026 | N-PORT |
| HRTS · Tema ETF Trust | 1,14% | 1.954 NS | 31 Maggio 2026 | N-PORT |
| MEDI · Harbor ETF Trust | 1,08% | 966 NS | 30 Aprile 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,90% | 15.151 NS | 30 Aprile 2026 | N-PORT |
| QQQE · Direxion Shares ETF Trust | 0,89% | 35.072 NS | 30 Aprile 2026 | N-PORT |
| VOT · VANGUARD INDEX FUNDS | 0,88% | 1.022.888 SH | 08 Agosto 2026 | Giornaliero |
| IWP · iShares Trust | 0,82% | 770.414 SH | 08 Agosto 2026 | Giornaliero |
| JOET · Virtus ETF Trust II | 0,80% | 6.062 NS | 30 Aprile 2026 | N-PORT |
| CGGR · Capital Group Growth ETF | 0,76% | 613.330 NS | 31 Maggio 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,66% | 60.901 NS | 30 Aprile 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,59% | 398.693 SH | 08 Agosto 2026 | Giornaliero |
| FFLG · FIDELITY COVINGTON TRUST | 0,58% | 11.032 NS | 30 Aprile 2026 | N-PORT |
| QNXT · iShares Trust | 0,54% | 699 SH | 08 Agosto 2026 | Giornaliero |
| USMV · iShares Trust | 0,47% | 527.555 SH | 08 Agosto 2026 | Giornaliero |
| IYH · iShares Trust | 0,47% | 79.894 SH | 08 Agosto 2026 | Giornaliero |
| VXF · VANGUARD INDEX FUNDS | 0,45% | 1.532.109 SH | 08 Agosto 2026 | Giornaliero |
| UPSD · ETF Series Solutions | 0,44% | 1.435 NS | 30 Aprile 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 0,43% | 4.118 NS | 31 Maggio 2026 | N-PORT |
| QFLR · Innovator ETFs Trust | 0,39% | 6.430 NS | 30 Aprile 2026 | N-PORT |
| VO · VANGUARD INDEX FUNDS | 0,39% | 2.893.468 SH | 08 Agosto 2026 | Giornaliero |
| IMCG · iShares Trust | 0,38% | 72.243 SH | 08 Agosto 2026 | Giornaliero |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,38% | 10.723 NS | 30 Aprile 2026 | N-PORT |
| ESMV · iShares Trust | 0,35% | 128 SH | 08 Agosto 2026 | Giornaliero |
| SDG · iShares Trust | 0,33% | 2.658 SH | 08 Agosto 2026 | Giornaliero |
| SMIZ · Zacks Trust | 0,31% | 2.688 NS | 31 Maggio 2026 | N-PORT |
| ESLG · Strategy Shares | 0,31% | 196 NS | 30 Aprile 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0,31% | 112 NS | 30 Aprile 2026 | N-PORT |
| HEQQ · J.P. Morgan Exchange-Traded Fund Tr… | 0,30% | 305 NS | 30 Aprile 2026 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,28% | 94 NS | 31 Maggio 2026 | N-PORT |
| HQGO · Lattice Strategies Trust | 0,26% | 404 NS | 30 Aprile 2026 | N-PORT |
| LRND · New York Life Investments ETF Trust | 0,24% | 2.252 NS | 30 Aprile 2026 | N-PORT |
| ESUM · Strategy Shares | 0,23% | 1.141 NS | 30 Aprile 2026 | N-PORT |
| FBCG · FIDELITY COVINGTON TRUST | 0,23% | 45.231 NS | 30 Aprile 2026 | N-PORT |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,22% | 15.559 NS | 30 Aprile 2026 | N-PORT |
| QCLR · Global X Funds | 0,21% | 27 NS | 30 Aprile 2026 | N-PORT |
| QYLG · Global X Funds | 0,21% | 953 NS | 30 Aprile 2026 | N-PORT |
| IWR · iShares Trust | 0,21% | 542.695 SH | 08 Agosto 2026 | Giornaliero |
| QRMI · Global X Funds | 0,21% | 108 NS | 30 Aprile 2026 | N-PORT |
| QYLD · Global X Funds | 0,20% | 54.832 NS | 30 Aprile 2026 | N-PORT |